Literature DB >> 21831177

A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management?

R S J Dalton1, R Velineni, M E Osborne, R Thomas, S Harries, A S Gee, I R Daniels.   

Abstract

AIM: The aim of the study was to assess the outcome of patients who received chemoradiotherapy (CRT) for locally advanced rectal cancer, specifically those with complete clinical response (CCR) and who were then managed nonoperatively with a 'Watch and Wait' follow-up protocol.
METHOD: A retrospective study was carried out of patients undergoing preoperative CRT for rectal cancer, conducted in a district general hospital managing rectal cancer through the multidisciplinary team process.
RESULTS: Forty-nine patients received preoperative CRT over a 5-year period (2004-2009). Twelve (24%) were considered potentially to have had a complete response on MRI. Of these, six subsequently had clinical evidence of residual disease, leading to surgery (mean time to surgery, 24 weeks; range, 12-36 weeks). The remaining six had CCR, avoiding surgery (mean follow up, 26 months; range, 12-45 months), with all six patients disease free to date. A further six patients had complete pathological response (CPR) following surgery after comprehensive histopathological assessment of the specimen.
CONCLUSION: In this consecutive series of patients with locally advanced rectal cancer treated with CRT, 12% demonstrated a CCR and have been actively managed conservatively, thereby avoiding surgery. With further improvements in diagnostic assessment of response to CRT, this figure may rise.
© 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21831177     DOI: 10.1111/j.1463-1318.2011.02752.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  41 in total

Review 1.  Complete radiotherapy response in rectal cancer: A review of the evidence.

Authors:  Daniel G Couch; David M Hemingway
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

2.  Focusing the management of rectal cancer.

Authors:  Rachel Dbeis; Neil J Smart; Ian R Daniels
Journal:  Ann Transl Med       Date:  2016-12

3.  Rectal cancer: is 'watch and wait' a safe option for rectal cancer?

Authors:  Bruce D Minsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-22       Impact factor: 46.802

Review 4.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 5.  Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer.

Authors:  Zeeshan Ramzan; Ammar B Nassri; Sergio Huerta
Journal:  World J Gastrointest Oncol       Date:  2014-07-15

6.  Systematic review and meta-analysis on outcomes of salvage therapy in patients with tumour recurrence during 'watch and wait' in rectal cancer.

Authors:  J On; J Shim; E H Aly
Journal:  Ann R Coll Surg Engl       Date:  2019-03-11       Impact factor: 1.891

7.  Management of distal rectal cancer: results from a national survey.

Authors:  G Melotti; E De Antoni; A Habr-Gama; A Minicozzi
Journal:  Updates Surg       Date:  2013-01-19

Review 8.  Update on advances and controversy in rectal cancer treatment.

Authors:  S Biondo; D Fraccalvieri; T Golda; R Frago; L Trenti; E Kreisler
Journal:  Tech Coloproctol       Date:  2016-01-12       Impact factor: 3.781

9.  Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision.

Authors:  Radhika K Smith; Robert D Fry; Najjia N Mahmoud; E Carter Paulson
Journal:  Int J Colorectal Dis       Date:  2015-03-19       Impact factor: 2.571

Review 10.  Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options.

Authors:  Daniel C Damin; Anderson R Lazzaron
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.